In vitro screening for chemokine antagonists

Expert Opinion on Drug Discovery

Volumn 4, Issue 10, 2009, Pages 1017-1034

  Ribeiro, Sofia ^b,c   Horuk, Richard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Metastatix ^*  (United States)

^c GENENTECH INC   (United States)

Author keywords

Antagonism; Chemokine receptors; Chemokines; GPCRs

Indexed keywords

BKT 140; BMS 741672; CCX 140; CCX 354; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; G PROTEIN COUPLED RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INCB 8696; INCB 9471; KW 0761; MARAVIROC; PF 4136309; PLERIXAFOR; POL 6326; PRO 140; REPERTAXIN; SB 656933; SCH 527123; TBR 652; TG 0054; TPI ASM 8; TRAFICET EN; UK 107543; UNCLASSIFIED DRUG; VICRIVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BINDING ASSAY; CALCIUM MOBILIZATION; CLINICAL TRIAL; DIMERIZATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; INFLAMMATORY DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RECEPTOR BINDING; REVIEW; STEM CELL MOBILIZATION;

EID: 70349386386     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440902956628     Document Type: Review

References (76)

1. Metchnikoff E. Lectures on the comparative pathology of inflammation. Keegan paul, trench, trubner and co., paternoster house, charing cross road. 1893. p. 218
2. Deuel TF, Keim PS, Farmer M, Heinrikson RL. Amino acid sequence of human platelet factor 4. Proc Natl Acad Sci USA 1977;74:2256-2258 (Pubitemid 8110689)
3. Walz A, Peveri P, Aschauer H, Baggiolini M. Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem Biophys Res Commun 1987;149:755-761 (Pubitemid 18023044)
4. Yoshimura T, Matsushima K, Tanaka S, et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 1987;84:9233-9237
5. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-568
6. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-127 (Pubitemid 30398626)
7. Fredriksson R, Schioth HB. The repertoire of g-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol 2005;67:1414-1425 (Pubitemid 40594140)
8. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-176
9. Horuk R, Chitnis CE, Darbonne WC, et al. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 1993;261:1182-1184 (Pubitemid 23300887)
10. van Berkel V, Barrett J, Tiffany HL, et al. Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J Virol 2000;74:6741-6747 (Pubitemid 30470656)
11. Loetscher P, Seitz M, Baggiolini M, Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med 1996;184:569-577 (Pubitemid 26324110)
12. Struyf S, Proost P, Schols D, et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999;162:4903-4909 (Pubitemid 29314895)
13. Petkovic V, Moghini C, Paoletti S, et al. Eotaxin-3/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5. A human chemokine with a regulatory role. J Biol Chem 2004;279:23357-23363 (Pubitemid 38685645)
14. Horuk R. Chemokine receptors. Growth Factor Rev 2001;12:313-335
15. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-4732
16. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2008;77:1656-1664
17. FDA Approval for Plerixafor. Available from: http://www.cancer.gov/ cancertopics/druginfo/fda-plerixafor
18. Ribeiro S, Horuk R. The clinical potential of chemokine receptor antagonists. Pharmacol Ther 2005;107:44-58 (Pubitemid 40803508)
19. Bennett GL, Horuk R. Iodination of chemokines for use in receptor binding analysis. Methods Enzymol 1997;288:134-148 (Pubitemid 27443765)
20. Schioppa T, Uranchimeg B, Saccani A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003;198:1391-1402 (Pubitemid 37392484)
21. New DC, Wong YH. Characterization of CHO cells stably expressing a G alpha 16/z chimera for high throughput screening of GPCRs. Assay Drug Dev Technol 2004;2:269-280
22. Kohler RE, Comerford I, Townley S, et al. Antagonism of the chemokine receptors CXCR3 and CXCR4 reduces the pathology of experimental autoimmune encephalomyelitis. Brain Pathol 2008;18:504-516
23. Cashen A, Lopez S, Gao F, et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:1253-1261
24. Hesselgesser J, Liang M, Hoxie J, et al. Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity. J Immunol 1998;160:877-883 (Pubitemid 28049330)
25. Schols D, Struyf S, Van Damme J, et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-1388 (Pubitemid 27469034)
26. Gupta SK, Pillarisetti K, Thomas RA, Aiyar N. Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. Immunol Lett 2001;78:29-34 (Pubitemid 32709903)
27. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008;112:990-998
28. Fransen S, Bridger G, Whitcomb JM, et al. Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition. Antimicrob Agents Chemother 2008;52:2608-2615 (Pubitemid 351915694)
29. Crump MP, Gong JH, Loetscher P, et al. Solution structure and basis for functional activity of stromal cell- derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. Embo J 1997;16:6996-7007 (Pubitemid 27520800)
30. Edwards BS, Oprea T, Prossnitz ER, Sklar LA. Flow cytometry for high-throughput, high-content screening. Curr Opin Chem Biol 2004;8:392-398 (Pubitemid 38993732)
31. Trinquet E, Fink M, Bazin H, et al. D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. Anal Biochem 2006;358:126-135
32. Bradley J, Gill J, Bertelli F, et al. Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry. J Biomol Screen 2004;9:516-524 (Pubitemid 40503527)
33. Armour D, de Groot MJ, Edwards M, et al. The discovery of CCR5 receptor antagonists for the treatment of HIV infection: hit-to-lead studies. ChemMedChem 2006;1:706-709 (Pubitemid 44154358)
34. Czaplewski LG, McKeating J, Craven CJ, et al. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. J Biol Chem 1999;274:16077-16084 (Pubitemid 129526353)
35. Neote K, DiGregorio D, Mak JY, et al. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 1993;72:415-425 (Pubitemid 23059411)
36. Van Riper G, Nicholson DW, Scheid MP, et al. Induction, characterization, and functional coupling of the high affinity chemokine receptor for RANTES and macrophage inflammatory protein-1 alpha upon differentiation of an eosinophilic HL-60 cell line. J Immunol 1994;152:4055-4061 (Pubitemid 24111077)
37. Taub DD, Proost P, Murphy WJ, et al. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest 1995;95:1370-1376
38. Kenakin T, Jenkinson S, Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 2006;319:710-723 (Pubitemid 44776375)
39. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377 (Pubitemid 26272077)
40. Ditzel HJ, Rosenkilde MM, Garred P, et al. Schwartz TW. The CCR5 receptor acts as an alloantigen in CCR5Delta32 homozygous individuals: identification of chemokineand HIV-1-blocking human antibodies. Proc Natl Acad Sci USA 1998;95:5241-5245
41. Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001;357:1758-1761
42. Napier C, Sale H, Mosley M, et al. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol 2005;71:163-172 (Pubitemid 41713538)
43. De Clercq E, Yamamoto N, Pauwels R, et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994;38:668-674 (Pubitemid 24113999)
44. Aids IL. Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791. Drugs R D 2007;7:113-119
45. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-1958 (Pubitemid 26234510)
46. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877
47. Schols D, Este JA, Henson G, et al. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997;35:147-156 (Pubitemid 27351415)
48. De Clercq E. Hamao umezawa memorial award lecture: "An Odyssey in the Viral Chemotherapy Field". Int J Antimicrob Agents 2001;18:309-328
49. Hatse S, Princen K, Bridger G, et al. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002;527:255-262 (Pubitemid 35253875)
50. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1253-1262
51. Gladue RP, Zwillich SH, Clucas AT, Brown MF. CCR1 antagonists for the treatment of autoimmune diseases. Curr Opin Investig Drugs 2004;5:499-504
52. Brown MF, Bahnck KB, Blumberg LC, et al. Piperazinyl CCR1 antagonists-optimization of human liver microsome stability. Bioorg Med Chem Lett 2007;17:3109-3112
53. Zipp F, Hartung HP, Hillert J, et al. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 2006;67:1880-1883 (Pubitemid 44900777)
54. Vann L. End of 2007 brings extra activity. Autoimmune Drug Focus 2007;37:1
55. Beaulieu A, Hasler F, Martin Mola E, et al. The efficacy and safety of a CCR2 receptor antagonist in the treatment of rheumatoid arthritis (RA). Ann Rheum Dis 2006;65(Suppl II):175. Avilable from: http://www.abstracts2view.com/ eular/ search.php?search=do&intMaxHits=10&w here[]=&andornot[]= &query=CCR12+ant agonist.
56. Braddock M. 11th annual Inflammatory and Immune Diseases Drug Discovery and Development Summit 12-13 March 2007, San Francisco, USA. Expert Opin Investig Drugs 2007;16:909-917
57. Braddock M. Advances in anti-inflammatory therapeutics: 20-21 November 2006, London, UK. Expert Opin Investig Drugs 2007;16:257-261
58. Johnson M, Li AR, Liu J, et al. Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg Med Chem Lett 2007;17:3339-3343 (Pubitemid 46819037)
59. Liang M, Mallari C, Rosser M, et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 2000;275:19000-19008 (Pubitemid 30422866)
60. Gladue RP, Tylaska LA, Brissette WH, et al. CP-481,715: a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J Biol Chem 2003;278:40473-40480
61. Gladue RP, Cole SH, Roach ML, et al. The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice. J Immunol 2006;176:3141-3148
62. Combadiere C, Potteaux S, Rodero M, et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008;117:1649-1657
63. Saederup N, Chan L, Lira SA, Charo IF. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation 2008;117:1642-1648
64. Walters I, Austin C, Austin R, et al. Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg Med Chem Lett 2008;18:798-803
65. Maggio R, Scarselli M, Novi F, et al. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem 2003;87:631-641
66. Hilairet S, Bouaboula M, Carriere D, et al. Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J Biol Chem 2003;278:23731-23737 (Pubitemid 36830197)
67. McGraw DW, Mihlbachler KA, Schwarb MR, et al. Liggett SB. Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J Clin Invest 2006;116:1400-1409
68. Rodriguez-Frade JM, Vila-Coro AJ, de Ana AM, et al. The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2. Proc Natl Acad Sci USA 1999;96:3628-3633
69. El-Asmar L, Springael JY, Ballet S, et al. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol 2005;67:460-469 (Pubitemid 40216739)
70. Vila-Coro AJ, Mellado M, Martin de Ana A, et al. HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. Proc Natl Acad Sci USA 2000;97:3388-3393 (Pubitemid 30183312)
71. Vila-Coro AJ, Rodriguez-Frade JM, Martin De Ana A, et al. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J 1999;13:1699-1710
72. Babcock GJ, Farzan M, Sodroski J. Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor. J Biol Chem 2003;278:3378-3385 (Pubitemid 36801253)
73. Trettel F, Di Bartolomeo S, Lauro C, et al. Ligand-independent CXCR2 dimerization. J Biol Chem 2003;278:40980-40988
74. Milligan G, Wilson S, Lopez-Gimenez JF. The specificity and molecular basis of alpha1-adrenoceptor and CXCR chemokine receptor dimerization. J Mol Neurosci 2005;26:161-168 (Pubitemid 41389408)
75. Smith MW, Carrington M, Winkler C, et al. CCR2 chemokine receptor and AIDS progression. Nat Med 1997;3:1052-1053 (Pubitemid 27444420)
76. Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, et al. Chemokine control of HIV-1 infection. Nature 1999;400:723-724